ArticleACS omega2020
Tuning Crystal Structures of Iron-Based Metal-Organic Frameworks for Drug Delivery Applications.
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 79 citations in OpenAlex.
- Article
- Magnetic 2D Transition-Metal-Based Nanomaterials in Biomedicine: Opportunities and Challenges in Cancer Therapy.Materials (Basel, Switzerland) · 2025Review
- Photoactivated Multivariate Metal-Organic Frameworks for On-Demand Drug Release: The Role of Host-Guest Interactions.Journal of the American Chemical Society · 2025Article
- Climate friendly MOFs synthesis for drug delivery systems by integrating AI, intelligent manufacturing, and quantum solutions in industry 6.0 sustainable approach.Toxicology research · 2025Review
- Metal-Organic Framework Thin Films as Drug Delivery Systems.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Core-Shell Magnetic Nanocarriers: FeInternational journal of nanomedicine · 2025Article
- Constructing Physiological Defense Systems against Infectious Disease with Metal-Organic Frameworks: A Review.ACS applied bio materials · 2023Review
- Fe-Based Metal Organic Frameworks (Fe-MOFs) for Bio-Related Applications.Pharmaceutics · 2023Review
- Metal-Organic Framework-Based Nanomedicines for the Treatment of Intracellular Bacterial Infections.Pharmaceutics · 2023Review
- Metal-Organic Frameworks and Their Biodegradable Composites for Controlled Delivery of Antimicrobial Drugs.Pharmaceutics · 2023Review
- Bibliometric and visualized analysis of metal-organic frameworks in biomedical application.Frontiers in bioengineering and biotechnology · 2023Article
- pH-Responsive Metal-Organic Framework Thin Film for Drug Delivery.Langmuir : the ACS journal of surfaces and colloids · 2022Article
- Iron-containing metal-organic framework thin film as a drug delivery system.Colloids and surfaces. A, Physicochemical and engineering aspects · 2022Article
- Anti-inflammatory and antioxidant effects of nanoformulations composed of metal-organic frameworks delivering rutin and/or piperine natural agents.Drug delivery · 2021Article
- Green construction of eco-friendly phosphotungstic acid Sr-MOF catalysts for crystal violet removal and synthesis of coumarin and xanthene compounds.RSC advances · 2021Article
- pH-triggered degradation and release of doxorubicin from zeolitic imidazolate framework-8 (ZIF8) decorated with polyacrylic acid.RSC advances · 2021Article
- Metal-Organic Frameworks for Drug Delivery: A Design Perspective.ACS applied materials & interfaces · 2021Review
- Adsorption of Amyloid Beta Peptide by Metal-Organic Frameworks.ACS omega · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Iron-based metal-organic frameworks (Fe-MOFs) have emerged as promising candidates for drug delivery applications due to their low toxicity, structural flexibility, and safe biodegradation in a physiological environment. Here, we studied two types of Fe-MOFs: MIL-53 and MIL-88B, for in vitro drug loading and releasing of ibuprofen as a model drug. Both Fe-MOFs are based on the same iron clusters and organic ligands but form different crystal structures as a result of two different nucleation pathways. The MIL-53 structure demonstrates one-dimensional channels, while MIL-88B exhibits a three-dimensional cage structure. Our studies show that MIL-53 adsorbs more ibuprofen (37.0 wt %) compared to MIL-88B (19.5 wt %). A controlled drug release was observed in both materials with a slower elution pattern in the case of the ibuprofen-encapsulated MIL-88B. This indicates that a complex cage structure of MIL-88 is beneficial to control the rate of drug release. A linear correlation was found between cumulative drug release and the degree of material degradation, suggesting the biodegradation of Fe-MILs as the main drug elution mechanism. The cytotoxicity of MIL-88B was evaluated in vitro with NIH-3T3 Swiss mouse fibroblasts, and it shows that MIL-88B has no adverse effects on cell viability up to 0.1 mg/mL. This low toxicity was attributed to the morphology of MIL-88B nanocrystals. The very low toxicity and controlled drug release behavior of Fe-MIL-88B suggest that better materials for drug-delivery applications can be created by controlling not only the composition but also the crystal structure and nanoparticle morphology of the material.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.